In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of BioAtla Inc (NASDAQ: BCAB) closed at $0.47 in the last session, down -9.28% from day before closing price of $0.52. In other words, the price has decreased by -$9.28 from its previous closing price. On the day, 0.99 million shares were traded.
Ratios:
We take a closer look at BCAB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.35 and its Current Ratio is at 2.35. In the meantime, Its Debt-to-Equity ratio is 1.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On September 15, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $17.
Credit Suisse Downgraded its Outperform to Neutral on May 05, 2022, whereas the target price for the stock was revised from $35 to $5.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.52 while its Price-to-Book (P/B) ratio in mrq is 50.62.
Stock Price History:
Over the past 52 weeks, BCAB has reached a high of $2.53, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is 19.72%, while the 200-Day Moving Average is calculated to be -53.95%.
Shares Statistics:
A total of 58.40M shares are outstanding, with a floating share count of 44.58M. Insiders hold about 23.69% of the company’s shares, while institutions hold 18.46% stake in the company.
